Stallergenes Greer announced that the following appointments to the company's corporate leadership and Board of Directors were confirmed and approved by the company's board of directors on 12 December 2018. Stefan Meister is appointed Chairman of the Board of Directors, Michele Antonelli is appointed member of the Board of Directors and Chief Executive Officer and Elmar Schnee is appointed Lead Independent Director. Fereydoun Firouz will retire from his position as Chairman and Chief Executive Officer at the end of 2018.

Effective 4 January 2019, and as announced in August 2018, Stefan Meister will take over as Chairman of the board of Directors and Michele Antonelli as Chief Executive Officer. Stefan Meisteris Group Chief Operating Officer of the Waypoint Group, a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family, which is also the indirect owner of Ares Life Sciences I S.a.r.l., Stallergenes Greer's largest shareholder. Michele Antonelli has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in manufacturing, commercial and general management.

Mr. Antonelli joined Stallergenes Greer in November 2015 as Executive Vice President, Head of International Operations. Elmar Schneehas more than 25 years' experience in the pharmaceutical industry. Mr. Schnee is currently Board Secretary of Mindmaze SA and was, from 2016 to March 2017, Chief Operating Officer.

Mr. Schnee is Chairman of the Board of Directors of Santhera AG, a Swiss speciality pharmaceutical company developing medicines for rare diseases. He is also a Member of the Board of Directors of Jazz Pharmaceuticals. From November 2013 to August 2015, Mr. Schnee served as a Non-Executive Director of Cardiorentis Ltd., a biopharmaceutical company, where he served as Chairman and Chief Executive Officer from October 2011 until November 2013.